Morepen Medipath, a subsidiary of Morepen Laboratories (NSE:MOREPENLAB, BOM:500288), has received board approval to incorporate a wholly-owned subsidiary in Dubai, according to a Monday filing to the Indian stock exchanges.
The new subsidiary aims to expand the company's business-to-consumer (B2C) and business-to-business (B2B) customer segments and provide greater access to the medical device business.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。